A number of research firms have changed their ratings and price targets for Agile Therapeutics (NASDAQ: AGRX): 5/11/2016 – Agile Therapeutics was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Agile Therapeutics, Inc. is a women’s health specialty pharmaceutical company. It is focused on the […]
